← Russell 3000 cross-section

ABBV AbbVie Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-03, not restated
Healthcare

Scale

Market cap
$457.2bn
Revenue TTM
$64.4bn
Net income TTM
$6.3bn
Free cash flow
$18.2bn
Composite score
51.8
Sector rank
#21

Valuation

P / E
72.5
EV / EBITDA
18.2
EV / sales
7.0
FCF yield
3.98%
Earnings yield vs 10-yr
-3.35pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
9.8%
EBITDA margin
38.4%
ROE
-106.3%
ROIC
Revenue growth
10.4%

Insider activity, last 90 days

Net open-market
$-8.18m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Worldwide net revenues increased 11% on a reported basis and 10% on a constant currency basis. Net revenues for Skyrizi increased 24% for the three months and 26% for the six months ended June 30, 2026 primarily driven by continued strong market share uptake as well as market growth across all indications. Net revenues for Rinvoq increased 24% for the three months and 22% for the six months ended June 30, 2026 primarily driven by continued strong market share uptake as well as market growth across all indications. …AbbVie Inc., 10-Q, period ended 2026-06-30, filed 2026-08-03

Read the full passage →